Anastasia O. Maksaeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anastasia O. Maksaeva has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Nikolaevich Orekhov
Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia
5 shared publications - Siarhei Alexander Dabravolski
Department of Biotechnology Engineering, Braude Academic College of Engineering, Snunit 51, P.O. Box 78, Karmiel 2161002, Israel
4 shared publications - Alexander V. Blagov
Laboratory of Molecular Genetic Modeling of Inflammaging, Institute of General Pathology and Pathophysiology, 8, Baltiiskaya Street, 125315 Moscow, Russia
3 shared publications - Vasiliy Nikolaevich Sukhorukov
Institute of General Pathology and Pathophysiology, Moscow, Russia
3 shared publications - Aleksandra S. Utkina
Institute for Atherosclerosis Research, Osennyaya Street 4-1-207, 121609 Moscow, Russia
2 shared publications - Gulalek Babayeva
Institute of Experimental Cardiology, National Medical Research Center of Cardiology, Moscow, Russia
2 shared publications
Latest Publications
- Open Access
Analysis of the Use of shRNA in Atherosclerosis Therapy: Current Status
Atherosclerosis remains the principal pathological substrate of myocardial infarction, ischemic stroke and peripheral artery disease, and its progression is driven by an interlocking set of processes, including hepatic and vascular lipid metabolism, chronic vascular inflammation, macrophage foam cell formation and vascular smooth muscle cell (VSMC) proliferation, none of which is fully controlled by currently approved pharmacotherapy. Short hairpin RNA (shRNA) technology, in which a DNA template encoding a stem-loop transcript is delivered to a cell and processed intracellularly into small interfering RNAs (siRNAs) that trigger sequence-specific mRNA degradation, offers a route to durable, vector-encoded gene silencing that is mechanistically distinct from transiently acting synthetic siRNA or antisense oligonucleotides and that, although non-permanent at the level of the target gene, is not readily reversible at the level of the vector, which cannot easily be withdrawn once administered. This review analyzes the current status of shRNA-based strategies for atherosclerosis therapy. We summarize the molecular mechanism and vector design principles of shRNA-mediated RNA interference (RNAi); critically examine preclinical studies in which shRNA delivered by lentiviral or adeno-associated viral (AAV) vectors has been used to silence hepatic lipid-metabolism genes (PCSK9, ApoB,), the endothelial gene ANGPTL2, inflammasome and inflammatory mediators (NLRP3, TACE/ADAM17), and genes driving VSMC proliferation in restenosis models (connexin 43); we explicitly distinguish this direct shRNA evidence from complementary target-validation studies that use antisense oligonucleotides (e.g., ANGPTL4), synthetic siRNA, genetic knockout, or antimiR approaches (e.g., lncRNA AK136714, CD36, miR-33, P2X7R); and discuss the principal delivery vectors, their tissue tropism, and the toxicity arising from saturation of the endogenous microRNA-processing machinery. We further place shRNA in the context of competing and complementary RNA-based and gene-editing modalities, including clinically approved synthetic siRNA drugs (inclisiran, patisiran) and CRISPR-based gene editing of PCSK9 and ANGPTL3, both of which have now yielded human phase 1 data, to clarify why, despite two decades of robust preclinical proof-of-concept, no shRNA construct has yet reached clinical use in atherosclerosis; we further compare this with the clinical trajectory of vector-encoded shRNA in other indications, in which anti-CCR5 and anti-HCV constructs have already been administered to patients in phase 1/2 trials, in order to establish that the limiting factor is not the hairpin itself but the risk–benefit case obtainable in a chronic, largely asymptomatic disease for which withdrawable and outcome-validated therapies already exist. We conclude that shRNA remains a mechanistically attractive but clinically immature modality whose translation will depend on vector engineering that limits off-target saturation of the RNAi pathway and achieves durable, cell type-restricted expression in the liver, endothelium, macrophages or vascular wall, and, equally, on the identification of an atherosclerosis indication—most plausibly a small, high-residual-risk or locally treatable population—in which durability outweighs the vector-level irreversibility, immunogenicity and manufacturing burden of a viral vector.
Open AccessAnalysis of the Use of shRNA in Atherosclerosis Therapy: Current Status
Atherosclerosis remains the principal pathological substrate of myocardial infarction, ischemic stroke and peripheral artery disease, and its progression is driven by an interlocking set of processes, including hepatic and vascular lipid metabolism, chronic vascular inflammation, macrophage foam cell formation and vascular smooth muscle cell (VSMC) proliferation, none of which is fully controlled by currently approved pharmacotherapy. Short hairpin RNA (shRNA) technology, in which a DNA template encoding a stem-loop transcript is delivered to a cell and processed intracellularly into small interfering RNAs (siRNAs) that trigger sequence-specific mRNA degradation, offers a route to durable, vector-encoded gene silencing that is mechanistically distinct from transiently acting synthetic siRNA or antisense oligonucleotides and that, although non-permanent at the level of the target gene, is not readily reversible at the level of the vector, which cannot easily be withdrawn once administered. This review analyzes the current status of shRNA-based strategies for atherosclerosis therapy. We summarize the molecular mechanism and vector design principles of shRNA-mediated RNA interference (RNAi); critically examine preclinical studies in which shRNA delivered by lentiviral or adeno-associated viral (AAV) vectors has been used to silence hepatic lipid-metabolism genes (PCSK9, ApoB,), the endothelial gene ANGPTL2, inflammasome and inflammatory mediators (NLRP3, TACE/ADAM17), and genes driving VSMC proliferation in restenosis models (connexin 43); we explicitly distinguish this direct shRNA evidence from complementary target-validation studies that use antisense oligonucleotides (e.g., ANGPTL4), synthetic siRNA, genetic knockout, or antimiR approaches (e.g., lncRNA AK136714, CD36, miR-33, P2X7R); and discuss the principal delivery vectors, their tissue tropism, and the toxicity arising from saturation of the endogenous microRNA-processing machinery. We further place shRNA in the context of competing and complementary RNA-based and gene-editing modalities, including clinically approved synthetic siRNA drugs (inclisiran, patisiran) and CRISPR-based gene editing of PCSK9 and ANGPTL3, both of which have now yielded human phase 1 data, to clarify why, despite two decades of robust preclinical proof-of-concept, no shRNA construct has yet reached clinical use in atherosclerosis; we further compare this with the clinical trajectory of vector-encoded shRNA in other indications, in which anti-CCR5 and anti-HCV constructs have already been administered to patients in phase 1/2 trials, in order to establish that the limiting factor is not the hairpin itself but the risk–benefit case obtainable in a chronic, largely asymptomatic disease for which withdrawable and outcome-validated therapies already exist. We conclude that shRNA remains a mechanistically attractive but clinically immature modality whose translation will depend on vector engineering that limits off-target saturation of the RNAi pathway and achieves durable, cell type-restricted expression in the liver, endothelium, macrophages or vascular wall, and, equally, on the identification of an atherosclerosis indication—most plausibly a small, high-residual-risk or locally treatable population—in which durability outweighs the vector-level irreversibility, immunogenicity and manufacturing burden of a viral vector.
- Open Access
- 15 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8215
CD80 as an Important Immune Mediator and Therapeutic Target in Atherosclerosis
Atherosclerosis is a chronic immune–inflammatory disease of the arterial wall in which antigen-presenting cells (dendritic cells, macrophages and B cells) present locally generated antigens, such as oxidized low-density lipoprotein, to plaque-infiltrating T cells. Full T-cell activation requires costimulation through the B7 family ligands CD80 (B7-1) and CD86 (B7-2), which engage CD28 to activate T cells and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to restrain them. Although long considered functionally redundant, CD80 and CD86 are now known to be structurally and mechanistically distinct, differing in receptor affinity, susceptibility to CTLA-4-mediated trans-endocytosis, capacity to cis-heterodimerize with programmed death-ligand 1, and dependence relationships with regulatory versus effector T cells. In atherosclerosis, CD80 is expressed by lesional dendritic cells, macrophages, foam cells, B cells and, under inflammatory conditions, vascular endothelial and smooth muscle cells, with expression levels correlating with plaque vulnerability in humans. Genetic deletion, CTLA-4-Ig-based pharmacological blockade and selective small-molecule antagonism in preclinical models generally converge on a proatherogenic role for CD80/CD86-dependent costimulation, although combined genetic deletion of CD80 and CD86 has also been reported to paradoxically enhance early lesion formation in some contexts, while augmented CTLA-4-mediated coinhibition is atheroprotective—a balance corroborated by the accelerated atherosclerosis and cardiovascular toxicity observed with checkpoint-inhibitor cancer immunotherapy. Molecular imaging agents targeting CD80/CD86, repurposed CTLA-4-Ig biologics such as abatacept, and antigen-specific tolerogenic dendritic cell strategies together constitute an emerging translational pipeline. To our knowledge, this is the first review to integrate CD80’s structural and receptor pharmacology with its cellular sources in the plaque, preclinical genetic and pharmacological evidence, human plaque and biomarker data, molecular imaging approaches, and checkpoint inhibitor-associated cardiovascular toxicity within a single translational framework. This review synthesizes the structural biology, cellular sources, preclinical genetics, human plaque and biomarker data, and therapeutic and diagnostic implications of CD80 as an immune mediator and candidate therapeutic target in atherosclerosis.
- 15 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8215
Open AccessCD80 as an Important Immune Mediator and Therapeutic Target in Atherosclerosis
Atherosclerosis is a chronic immune–inflammatory disease of the arterial wall in which antigen-presenting cells (dendritic cells, macrophages and B cells) present locally generated antigens, such as oxidized low-density lipoprotein, to plaque-infiltrating T cells. Full T-cell activation requires costimulation through the B7 family ligands CD80 (B7-1) and CD86 (B7-2), which engage CD28 to activate T cells and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to restrain them. Although long considered functionally redundant, CD80 and CD86 are now known to be structurally and mechanistically distinct, differing in receptor affinity, susceptibility to CTLA-4-mediated trans-endocytosis, capacity to cis-heterodimerize with programmed death-ligand 1, and dependence relationships with regulatory versus effector T cells. In atherosclerosis, CD80 is expressed by lesional dendritic cells, macrophages, foam cells, B cells and, under inflammatory conditions, vascular endothelial and smooth muscle cells, with expression levels correlating with plaque vulnerability in humans. Genetic deletion, CTLA-4-Ig-based pharmacological blockade and selective small-molecule antagonism in preclinical models generally converge on a proatherogenic role for CD80/CD86-dependent costimulation, although combined genetic deletion of CD80 and CD86 has also been reported to paradoxically enhance early lesion formation in some contexts, while augmented CTLA-4-mediated coinhibition is atheroprotective—a balance corroborated by the accelerated atherosclerosis and cardiovascular toxicity observed with checkpoint-inhibitor cancer immunotherapy. Molecular imaging agents targeting CD80/CD86, repurposed CTLA-4-Ig biologics such as abatacept, and antigen-specific tolerogenic dendritic cell strategies together constitute an emerging translational pipeline. To our knowledge, this is the first review to integrate CD80’s structural and receptor pharmacology with its cellular sources in the plaque, preclinical genetic and pharmacological evidence, human plaque and biomarker data, molecular imaging approaches, and checkpoint inhibitor-associated cardiovascular toxicity within a single translational framework. This review synthesizes the structural biology, cellular sources, preclinical genetics, human plaque and biomarker data, and therapeutic and diagnostic implications of CD80 as an immune mediator and candidate therapeutic target in atherosclerosis.
- Open Access
- 4 November 2025
- Published by Springer Nature in Research Square
1 TESLA MRI AND MIP ANALYSIS FOR CUPRIZONE-INDUCED DEMYELINATION ASSESEMENT IN C57BL/6 MICE
Purpose This study aimed to develop and validate an imaging-based approach using 1Tesla MRI to assess brain lesion area in a cuprizone-induced demyelination model of multiple sclerosis in mice. Methods Demyelination was induced in C57Bl/6 mice through a cuprizone-supplemented diet. Magnetic resonance imaging was performed regularly using a 1 Tesla permanent magnet system to monitor disease progression. Following the cuprizone feeding, mice received intraperitoneal injections of vindeburnol for 60 days, with continued MRI monitoring throughout the treatment period. Brain lesion areas were quantified using maximum intensity projection (MIP) analysis of axial and sagittal images, with contrast enhancement achieved through administration of gadopentetate dimeglumine (Magnevsit ®) Results After 90 days on the cuprizone diet, demyelination was confirmed by an increase in contrast- enhanced lesion areas on 1Tesla MRI, elevated clinical scores and histology. A subsequent 60-day course of vindeburnol treatment led to a 1.2-fold improvement in recovery compared to the spontaneous recovery group. Statistically significant reductions in both lesion area and signal intensity were observed in the vindeburnol-treated group compared to the untreated control (P < 0.001) and the spontaneous recovery group (P < 0.05). Conclusion Contrast-enhanced 1Tesla MRI combined with MIP analysis proved to be a reliable and effective method for quantifying brain lesions and evaluating therapeutic response in the cuprizone- induced demyelination model.
- 4 November 2025
- Published by Springer Nature in Research Square
Open Access1 TESLA MRI AND MIP ANALYSIS FOR CUPRIZONE-INDUCED DEMYELINATION ASSESEMENT IN C57BL/6 MICE
Purpose This study aimed to develop and validate an imaging-based approach using 1Tesla MRI to assess brain lesion area in a cuprizone-induced demyelination model of multiple sclerosis in mice. Methods Demyelination was induced in C57Bl/6 mice through a cuprizone-supplemented diet. Magnetic resonance imaging was performed regularly using a 1 Tesla permanent magnet system to monitor disease progression. Following the cuprizone feeding, mice received intraperitoneal injections of vindeburnol for 60 days, with continued MRI monitoring throughout the treatment period. Brain lesion areas were quantified using maximum intensity projection (MIP) analysis of axial and sagittal images, with contrast enhancement achieved through administration of gadopentetate dimeglumine (Magnevsit ®) Results After 90 days on the cuprizone diet, demyelination was confirmed by an increase in contrast- enhanced lesion areas on 1Tesla MRI, elevated clinical scores and histology. A subsequent 60-day course of vindeburnol treatment led to a 1.2-fold improvement in recovery compared to the spontaneous recovery group. Statistically significant reductions in both lesion area and signal intensity were observed in the vindeburnol-treated group compared to the untreated control (P < 0.001) and the spontaneous recovery group (P < 0.05). Conclusion Contrast-enhanced 1Tesla MRI combined with MIP analysis proved to be a reliable and effective method for quantifying brain lesions and evaluating therapeutic response in the cuprizone- induced demyelination model.
- 16 July 2025
- Published by Springer Nature in Journal of Physiology and Biochemistry
- Vol. 81 (4) , 847-865
Purinergic receptors in atherosclerosis: implications for pathophysiology and therapeutic strategies
Atherosclerosis is a complex cardiovascular disease characterised by the accumulation of lipids, inflammatory cells, and fibrous elements within arterial walls, leading to plaque formation and increased risk of cardiovascular events. Recent evidence highlights the pivotal roles of purinergic receptors in mediating the inflammatory and cellular processes associated with atherosclerosis. This review examines the roles of purinergic receptors in the pathophysiology of atherosclerosis, with a particular focus on the P1 subtype (A2A and A3 receptors), the P2X subtype (P2X4 and P2X7 receptors), and the P2Y subtype (P2Y2, P2Y11, and P2Y12 receptors). The A2A and A3 receptors are involved in modulating vascular inflammation, endothelial cell function, and vascular smooth muscle cell calcification. P2X4 has been implicated in the production of pro-inflammatory cytokines and the promotion of plaque inflammation, whereas P2X7 contributes to vascular inflammation, plaque progression, and rupture. The P2Y2 receptor plays critical roles in regulating vascular inflammation and calcification, smooth muscle cell migration, and plaque growth. Furthermore, the P2Y11 receptor has been shown to modulate endothelial cell inflammation, while P2Y12 is associated with lipid accumulation, foam cell formation, vascular smooth muscle cell migration, and plaque development. By synthesising current knowledge on the involvement of purinergic signalling in atherosclerosis, this review discusses potential therapeutic targets for intervention. Specifically, P2Y receptor antagonists present promising avenues for reducing inflammation and improving vascular function in atherosclerotic patients. However, despite the advancements in understanding purinergic receptor functions, challenges remain in translating this knowledge into clinical practice. Further research is essential to unravel the intricate signalling pathways of these receptors and to develop effective biomarker strategies and therapeutic interventions aimed at combatting atherosclerosis and its associated complications.
- 16 July 2025
- Published by Springer Nature in Journal of Physiology and Biochemistry
- Vol. 81 (4) , 847-865
Purinergic receptors in atherosclerosis: implications for pathophysiology and therapeutic strategies
Atherosclerosis is a complex cardiovascular disease characterised by the accumulation of lipids, inflammatory cells, and fibrous elements within arterial walls, leading to plaque formation and increased risk of cardiovascular events. Recent evidence highlights the pivotal roles of purinergic receptors in mediating the inflammatory and cellular processes associated with atherosclerosis. This review examines the roles of purinergic receptors in the pathophysiology of atherosclerosis, with a particular focus on the P1 subtype (A2A and A3 receptors), the P2X subtype (P2X4 and P2X7 receptors), and the P2Y subtype (P2Y2, P2Y11, and P2Y12 receptors). The A2A and A3 receptors are involved in modulating vascular inflammation, endothelial cell function, and vascular smooth muscle cell calcification. P2X4 has been implicated in the production of pro-inflammatory cytokines and the promotion of plaque inflammation, whereas P2X7 contributes to vascular inflammation, plaque progression, and rupture. The P2Y2 receptor plays critical roles in regulating vascular inflammation and calcification, smooth muscle cell migration, and plaque growth. Furthermore, the P2Y11 receptor has been shown to modulate endothelial cell inflammation, while P2Y12 is associated with lipid accumulation, foam cell formation, vascular smooth muscle cell migration, and plaque development. By synthesising current knowledge on the involvement of purinergic signalling in atherosclerosis, this review discusses potential therapeutic targets for intervention. Specifically, P2Y receptor antagonists present promising avenues for reducing inflammation and improving vascular function in atherosclerotic patients. However, despite the advancements in understanding purinergic receptor functions, challenges remain in translating this knowledge into clinical practice. Further research is essential to unravel the intricate signalling pathways of these receptors and to develop effective biomarker strategies and therapeutic interventions aimed at combatting atherosclerosis and its associated complications.
- 4 July 2025
- Published by Springer Nature in Journal of Physiology and Biochemistry
- Vol. 81 (3) , 573-587
The role of cell junctions in atherosclerosis: implications for inflammation, endothelial dysfunction, and plaque stability
Atherosclerosis, a chronic inflammatory disease, involves a complex interplay between endothelial cells, smooth muscle cells, and inflammatory mediators. Cell-to-cell junctions, including adherens junctions (AJs), tight junctions (TJs), and gap junctions (GJs), play a critical role in maintaining vascular integrity and regulating cellular interactions in the vascular wall. This review summarises the molecular mechanisms by which these junctions contribute to atherosclerosis, focusing on key proteins like VE-cadherin (AJs), ZO-1, occludin, and claudins (TJs), and connexins (GJs). Dysregulation of these junctions, driven by factors such as oxidative stress, pro-inflammatory cytokines, atheroprone shear stress (aSS), and lipid-mediated signalling pathways, leads to endothelial dysfunction, increased permeability, monocyte infiltration, and plaque instability. Furthermore, the role of signalling pathways, including NFκB, PI3K/AKT, and Wnt/β-catenin, in the regulation of junctional proteins is explored. Emerging factors, including oxygenated cholesterol, radiation, and various drugs, provide new insights into junctional modulation in atherosclerosis. The potential of targeting junctional proteins and their associated pathways for therapeutic interventions is also discussed. Future studies focusing on the detailed mechanisms of junctional dysregulation in vivo and the clinical translation of these findings are necessary to develop novel therapeutic strategies for atherosclerosis. Clinical trial number Not applicable.
- 4 July 2025
- Published by Springer Nature in Journal of Physiology and Biochemistry
- Vol. 81 (3) , 573-587
The role of cell junctions in atherosclerosis: implications for inflammation, endothelial dysfunction, and plaque stability
Atherosclerosis, a chronic inflammatory disease, involves a complex interplay between endothelial cells, smooth muscle cells, and inflammatory mediators. Cell-to-cell junctions, including adherens junctions (AJs), tight junctions (TJs), and gap junctions (GJs), play a critical role in maintaining vascular integrity and regulating cellular interactions in the vascular wall. This review summarises the molecular mechanisms by which these junctions contribute to atherosclerosis, focusing on key proteins like VE-cadherin (AJs), ZO-1, occludin, and claudins (TJs), and connexins (GJs). Dysregulation of these junctions, driven by factors such as oxidative stress, pro-inflammatory cytokines, atheroprone shear stress (aSS), and lipid-mediated signalling pathways, leads to endothelial dysfunction, increased permeability, monocyte infiltration, and plaque instability. Furthermore, the role of signalling pathways, including NFκB, PI3K/AKT, and Wnt/β-catenin, in the regulation of junctional proteins is explored. Emerging factors, including oxygenated cholesterol, radiation, and various drugs, provide new insights into junctional modulation in atherosclerosis. The potential of targeting junctional proteins and their associated pathways for therapeutic interventions is also discussed. Future studies focusing on the detailed mechanisms of junctional dysregulation in vivo and the clinical translation of these findings are necessary to develop novel therapeutic strategies for atherosclerosis. Clinical trial number Not applicable.
- 16 April 2025
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 480 (8) , 4647-4670
Preclinical and mechanistic perspectives on adipose-derived stem cells for atherosclerotic cardiovascular disease treatment
Adipose-derived mesenchymal stem cells (AD-MSCs) are a promising therapeutic modality for cardiovascular diseases due to their immunomodulatory, anti-inflammatory, and pro-angiogenic properties. This manuscript explores the current status, challenges, and future directions of AD-MSC therapies, focusing on their application in atherosclerosis (AS), myocardial infarction (MI), and heart failure (HF). Preclinical studies highlight AD-MSC’s ability to stabilise atherosclerotic plaques, reduce inflammation, and enhance myocardial repair through mechanisms such as macrophage polarisation, endothelial protection, and angiogenesis. Genetically and pharmacologically modified AD-MSCs, including those overexpressing SIRT1, IGF-1, and PD-L1 or primed with bioactive compounds, exhibit superior efficacy compared to unmodified cells. These modifications enhance cell survival, immunopotency, and reparative capacity, showcasing the potential for tailored therapies. However, clinical translation faces significant hurdles. While recent clinical trials have confirmed the safety of AD-MSC therapy, their efficacy remains inconsistent, necessitating further optimisation of patient selection, dosing strategies, and delivery methods. Donor variability, particularly in patients with co-morbidities like type 2 diabetes (T2D) or obesity, impairs AD-MSC efficacy. Emerging research on extracellular vesicles (EVs) derived from AD-MSC offers a promising cell-free alternative, retaining the therapeutic benefits while mitigating risks. Future perspectives emphasise the need for multidisciplinary approaches to overcome these limitations. Strategies include refining genetic modifications, exploring EV-based therapies, and integrating personalised medicine and advanced diagnostic tools. By addressing these challenges, AD-MSC therapies hold the potential to revolutionise the treatment of cardiovascular diseases, providing innovative solutions to improve patient outcomes. Graphical abstract
- 16 April 2025
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 480 (8) , 4647-4670
Preclinical and mechanistic perspectives on adipose-derived stem cells for atherosclerotic cardiovascular disease treatment
Adipose-derived mesenchymal stem cells (AD-MSCs) are a promising therapeutic modality for cardiovascular diseases due to their immunomodulatory, anti-inflammatory, and pro-angiogenic properties. This manuscript explores the current status, challenges, and future directions of AD-MSC therapies, focusing on their application in atherosclerosis (AS), myocardial infarction (MI), and heart failure (HF). Preclinical studies highlight AD-MSC’s ability to stabilise atherosclerotic plaques, reduce inflammation, and enhance myocardial repair through mechanisms such as macrophage polarisation, endothelial protection, and angiogenesis. Genetically and pharmacologically modified AD-MSCs, including those overexpressing SIRT1, IGF-1, and PD-L1 or primed with bioactive compounds, exhibit superior efficacy compared to unmodified cells. These modifications enhance cell survival, immunopotency, and reparative capacity, showcasing the potential for tailored therapies. However, clinical translation faces significant hurdles. While recent clinical trials have confirmed the safety of AD-MSC therapy, their efficacy remains inconsistent, necessitating further optimisation of patient selection, dosing strategies, and delivery methods. Donor variability, particularly in patients with co-morbidities like type 2 diabetes (T2D) or obesity, impairs AD-MSC efficacy. Emerging research on extracellular vesicles (EVs) derived from AD-MSC offers a promising cell-free alternative, retaining the therapeutic benefits while mitigating risks. Future perspectives emphasise the need for multidisciplinary approaches to overcome these limitations. Strategies include refining genetic modifications, exploring EV-based therapies, and integrating personalised medicine and advanced diagnostic tools. By addressing these challenges, AD-MSC therapies hold the potential to revolutionise the treatment of cardiovascular diseases, providing innovative solutions to improve patient outcomes. Graphical abstract
- 27 March 2025
- Published by Springer Nature in Apoptosis
- Vol. 30 (5-6) , 1216-1234
Necroptosis in myocardial ischaemia-reperfusion injury: current update on mechanisms, therapeutic targets, and translational potential
Necroptosis is a programmed form of cell death that has gained significant attention in the field of cardiovascular research due to its involvement in myocardial infarction (MI) and myocardial ischaemia-reperfusion (I/R) injury. Unlike apoptosis, necroptosis elicits a pro-inflammatory response, contributing to myocardial injury, fibrosis, and adverse remodelling. This review aims to provide an overview of the molecular mechanisms underlying necroptosis, with a particular focus on its role in myocardial I/R injury. Key regulatory proteins such as Receptor-interacting protein kinase 3 (RIPK3) and Mixed lineage kinase domain-like protein (MLKL) are central to the necroptotic process, mediating cell death and inflammation. The review discusses the potential of targeting necroptosis as a therapeutic strategy for managing cardiovascular diseases, particularly post-MI. The RIPK3-CaMKII-mitochondrial permeability transition pore (mPTP) pathway is identified as a critical signalling axis in necroptosis and its inhibition may offer protective benefits in myocardial injury. The review also considers the role of natural and chemical inhibitors and other genes in necroptosis regulation. Overall, targeting necroptosis represents a promising avenue for therapeutic intervention to mitigate cardiac injury, promote recovery, and improve long-term patient outcomes in cardiovascular diseases.
- 27 March 2025
- Published by Springer Nature in Apoptosis
- Vol. 30 (5-6) , 1216-1234
Necroptosis in myocardial ischaemia-reperfusion injury: current update on mechanisms, therapeutic targets, and translational potential
Necroptosis is a programmed form of cell death that has gained significant attention in the field of cardiovascular research due to its involvement in myocardial infarction (MI) and myocardial ischaemia-reperfusion (I/R) injury. Unlike apoptosis, necroptosis elicits a pro-inflammatory response, contributing to myocardial injury, fibrosis, and adverse remodelling. This review aims to provide an overview of the molecular mechanisms underlying necroptosis, with a particular focus on its role in myocardial I/R injury. Key regulatory proteins such as Receptor-interacting protein kinase 3 (RIPK3) and Mixed lineage kinase domain-like protein (MLKL) are central to the necroptotic process, mediating cell death and inflammation. The review discusses the potential of targeting necroptosis as a therapeutic strategy for managing cardiovascular diseases, particularly post-MI. The RIPK3-CaMKII-mitochondrial permeability transition pore (mPTP) pathway is identified as a critical signalling axis in necroptosis and its inhibition may offer protective benefits in myocardial injury. The review also considers the role of natural and chemical inhibitors and other genes in necroptosis regulation. Overall, targeting necroptosis represents a promising avenue for therapeutic intervention to mitigate cardiac injury, promote recovery, and improve long-term patient outcomes in cardiovascular diseases.
- 1 January 2025
- Published by Eman Research Publishing LLC in Journal of Angiotherapy
- Vol. 9 (1) , 1-8
Autoimmunity and Chronic Inflammation in the Development of Atherosclerosis: New Treatment Strategies
Atherosclerosis, the leading cause of cardiovascular diseases, is a chronic inflammatory disorder driven by complex interactions between the innate and adaptive immune systems. Extensive research in both preclinical models and human studies has established the critical role of immune cells in sustaining vascular inflammation and promoting plaque development. Monocytes/macrophages, lymphocytes, neutrophils, mast cells, NK cells, and dendritic cells infiltrate atherosclerotic plaques, influencing disease progression through their activation and cytokine-mediated responses. Single-cell transcriptomic analyses have revealed distinct immune cell phenotypes, emphasizing their heterogeneity and functional dynamics in plaque formation, rupture, and resolution. Understanding the pathways involved in immune cell homing, activation, and regulation is essential for developing targeted therapies. Emerging anti-inflammatory interventions have shown promise in clinical trials, including IL-1β inhibitors (canakinumab), IL-6 antagonists (ziltivekimab), NLRP3 inflammasome inhibitors (colchicine, dapansutrile), and p38 MAPK inhibitors (losmapimod). These therapies aim to modulate inflammatory signaling and reduce cardiovascular risk. Additionally, nanoparticle-based imaging and drug delivery strategies are being explored to enhance precision medicine approaches in stabilizing plaques. However, balancing immune suppression with maintaining vascular homeostasis remains a challenge, necessitating further research to optimize therapeutic efficacy. This review provides an updated perspective on the immunological mechanisms underlying atherosclerosis and highlights novel anti-inflammatory strategies with potential clinical implications for cardiovascular disease management.
- 1 January 2025
- Published by Eman Research Publishing LLC in Journal of Angiotherapy
- Vol. 9 (1) , 1-8
Autoimmunity and Chronic Inflammation in the Development of Atherosclerosis: New Treatment Strategies
Atherosclerosis, the leading cause of cardiovascular diseases, is a chronic inflammatory disorder driven by complex interactions between the innate and adaptive immune systems. Extensive research in both preclinical models and human studies has established the critical role of immune cells in sustaining vascular inflammation and promoting plaque development. Monocytes/macrophages, lymphocytes, neutrophils, mast cells, NK cells, and dendritic cells infiltrate atherosclerotic plaques, influencing disease progression through their activation and cytokine-mediated responses. Single-cell transcriptomic analyses have revealed distinct immune cell phenotypes, emphasizing their heterogeneity and functional dynamics in plaque formation, rupture, and resolution. Understanding the pathways involved in immune cell homing, activation, and regulation is essential for developing targeted therapies. Emerging anti-inflammatory interventions have shown promise in clinical trials, including IL-1β inhibitors (canakinumab), IL-6 antagonists (ziltivekimab), NLRP3 inflammasome inhibitors (colchicine, dapansutrile), and p38 MAPK inhibitors (losmapimod). These therapies aim to modulate inflammatory signaling and reduce cardiovascular risk. Additionally, nanoparticle-based imaging and drug delivery strategies are being explored to enhance precision medicine approaches in stabilizing plaques. However, balancing immune suppression with maintaining vascular homeostasis remains a challenge, necessitating further research to optimize therapeutic efficacy. This review provides an updated perspective on the immunological mechanisms underlying atherosclerosis and highlights novel anti-inflammatory strategies with potential clinical implications for cardiovascular disease management.